Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2013 Oct 15;12(12):2827–2836. doi: 10.1158/1535-7163.MCT-13-0383

Figure 2.

Figure 2

Three-day biodistribution of 125I-labeled chTNT-3 administered at (A) 1 d, 2 d, or 3 d after pretreatment with VP-16 (30 mg/kg) in MAD109 bearing BALB/c mice and (B) of 125I-labeled chTNT-3 administered 1 d after 5-FU (50 mg/kg) in LS174T-bearing nude mice. Error bars represent standard error of the mean. * p < 0.05, ** p < 0.01, *** p < 0.001 as determine using one-way ANOVA followed by Tukey's post-hoc test (A) and two-tailed Student's t-test (B). N = 4 mice for all groups.